← brief for 2026-10-22 · Slowing decline

Heterogeneity in the treatment effect of sodium-glucose cotransporter-2 inhibitor on chronic kidney disease risk reduction: a prevalent new user cohort study applying double/debiased machine learning.

Article C Peer reviewed Observational

Key takeaways

This study looked at 2,280 people with type 2 diabetes to see how a kidney-protecting drug called an SGLT2 inhibitor works. It used a computer model to find that the drug helps some people more than others. This is an observational study, so it shows a link but not proof of cause.

Who did this work

Kongmalai T · Looareesuwan P · Tansawet A · Siriyotha S · Kunakorntham P · Boonwatcharapai B · Attia J · McKay GJ · Thakkinstian A

Source

Article · PubMed, the drug frontier · 2026 Jul 26
https://pubmed.ncbi.nlm.nih.gov/42908014/